» Articles » PMID: 38951523

Identification of Metabolites Reproducibly Associated with Parkinson's Disease Via Meta-analysis and Computational Modelling

Overview
Date 2024 Jul 1
PMID 38951523
Authors
Affiliations
Soon will be listed here.
Abstract

Many studies have reported metabolomic analysis of different bio-specimens from Parkinson's disease (PD) patients. However, inconsistencies in reported metabolite concentration changes make it difficult to draw conclusions as to the role of metabolism in the occurrence or development of Parkinson's disease. We reviewed the literature on metabolomic analysis of PD patients. From 74 studies that passed quality control metrics, 928 metabolites were identified with significant changes in PD patients, but only 190 were replicated with the same changes in more than one study. Of these metabolites, 60 exclusively increased, such as 3-methoxytyrosine and glycine, 54 exclusively decreased, such as pantothenic acid and caffeine, and 76 inconsistently changed in concentration in PD versus control subjects, such as ornithine and tyrosine. A genome-scale metabolic model of PD and corresponding metabolic map linking most of the replicated metabolites enabled a better understanding of the dysfunctional pathways of PD and the prediction of additional potential metabolic markers from pathways with consistent metabolite changes to target in future studies.

Citing Articles

Genomic and Transcriptomic Approaches Advance the Diagnosis and Prognosis of Neurodegenerative Diseases.

Liu Z, Song S Genes (Basel). 2025; 16(2).

PMID: 40004464 PMC: 11855287. DOI: 10.3390/genes16020135.


Evolving Landscape of Parkinson's Disease Research: Challenges and Perspectives.

Tenchov R, Sasso J, Zhou Q ACS Omega. 2025; 10(2):1864-1892.

PMID: 39866628 PMC: 11755173. DOI: 10.1021/acsomega.4c09114.


Omics data integration suggests a potential idiopathic Parkinson's disease signature.

Zagare A, Preciat G, Nickels S, Luo X, Monzel A, Gomez-Giro G Commun Biol. 2023; 6(1):1179.

PMID: 37985891 PMC: 10662437. DOI: 10.1038/s42003-023-05548-w.

References
1.
Crotty G, Maciuca R, Macklin E, Wang J, Montalban M, Davis S . Association of caffeine and related analytes with resistance to Parkinson disease among mutation carriers: A metabolomic study. Neurology. 2020; 95(24):e3428-e3437. PMC: 7836665. DOI: 10.1212/WNL.0000000000010863. View

2.
DAndrea G, Pizzolato G, Gucciardi A, Stocchero M, Giordano G, Baraldi E . Different Circulating Trace Amine Profiles in De Novo and Treated Parkinson's Disease Patients. Sci Rep. 2019; 9(1):6151. PMC: 6467876. DOI: 10.1038/s41598-019-42535-w. View

3.
Lim K, Dawson V, Dawson T . Parkin-mediated lysine 63-linked polyubiquitination: a link to protein inclusions formation in Parkinson's and other conformational diseases?. Neurobiol Aging. 2005; 27(4):524-9. DOI: 10.1016/j.neurobiolaging.2005.07.023. View

4.
Kumari S, Kumaran S, Goyal V, Sharma R, Sinha N, Dwivedi S . Identification of potential urine biomarkers in idiopathic parkinson's disease using NMR. Clin Chim Acta. 2020; 510:442-449. DOI: 10.1016/j.cca.2020.08.005. View

5.
Yakhine-Diop S, Morales-Garcia J, Niso-Santano M, Gonzalez-Polo R, Uribe-Carretero E, Martinez-Chacon G . Metabolic alterations in plasma from patients with familial and idiopathic Parkinson's disease. Aging (Albany NY). 2020; 12(17):16690-16708. PMC: 7521510. DOI: 10.18632/aging.103992. View